Join the 'Blepharospasm' group to help and get support from people like you. How it works
Blepharospasm Blog
| Tweet |
FDA Approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Posted 2 Aug 2010 by Drugs.com
GREENSBORO, N.C., Aug. 2 /PRNewswire/ – Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S. "This is an important regulatory milestone for Xeomin and is key to establishing our neurology business in the U.S.," said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC. "We at Merz understand, and are committed to, addressing the complexities of treating and living with these neurological disorders." The FDA approval of Xeomin is based on the results of two pivotal U.S. clinical trials ... Read more
Related support groups: Cervical Dystonia, Blepharospasm